FORMULATION AND EVALUATION OF VENLAFAXINE HYDROCHLORIDE SUSTAINED RELEASE MATRIX TABLET

  • Mahesh Pg* Department of Pharmaceutics, School of Pharmaceutical Sciences, Vels Institute of Science Technology and Advanced Studies, Pallavaram,Chennai, India.

Abstract

Aim: The term modified-release drug product is used to describe products that alter the timing and/or the rate of release of the drug substance.

Objective: The objective of the present study was to formulate and evaluate the sustained release matrix tablet of venlafaxine hydrochloride.

Methods: Venlafaxine hydrochloride is a structurally novel antidepressant for oral administration. It is widely prescribed for the treatment of depression, generalized anxiety disorder, and social anxiety disorder. Venlafaxine hydrochloride is currently available as immediate release tablet and as an extended release capsules under the brand names of Effexor (WYETH AYERST) and Effexor XR (WYETH AYERST). The biological half-life of venlafaxine very short (5 h) and the dose is to be taken 2–3 times a day and the recommended maximum daily dose is 75–450 mg/day. Venlafaxine hydrochloride is an antidepressant and so it is to be taken for quite a long period. Hence, to reduce the dosing frequency, simple, lower cost sustained release tablets of venlafaxine were preferred for the development.

Conclusion: The venlafaxine hydrochloride sustained release matrix tablets shown controlled release profile as per the release profile of

the innovator is EffexorTm_XR. The sustained release of this matrix tablet reduces the dosing frequency and reduces the side effects, by

which in a long-term therapy, it may be useful as a product with patient compliance for the treatment of major depression disorder.

Keywords: Venlafaxine hydrochloride, Hydroxypropyl methylcellulose, Matrix tablets.

References

1. Avachat A, Kotwal V. Design and evaluation of matrix-based controlled release tablets of diclofenac sodium and chondroitin sulphate. AAPS PharmSciTech 2007;8:E88.
2. Kuksal A, Tiwary AK, Jain NK, Jain S. Formulation and in vitro, in vivo evaluation of extended-release matrix tablet of zidovudine: Influence of combination of hydrophilic and hydrophobic matrix formers. AAPS PharmSciTech 2006;7:E1.
3. Basak SC, Reddy BM, Mani KP. Formulation and release behaviour of sustained release ambroxol hydrochloride HPMC matrix tablet. Indian J Pharm Sci 2006;3:594-7.
4. Bhalla HL, Handa AK. Development and evaluation of controlled release tablets of carbamazepine. Indian Drugs 1999;36:l00-5.
5. Bolton S, Bon C. Pharmaceutical Statistics: Practical and Clinical Applications. New York: Marcel Dekker; 2004.
6. Boume DW. Pharmacokinetics. In: Banker GS, Rhodes CT, editors. Modern Pharmaceutics. 4th ed. New York, NY: Marcel Dekker; 2002. p. 67-92.
7. Bramhanker DM, Jaiswal SB. Controlled release medications. In: Biopharmaceutics and Pharmacokinetics a Treatise. New Delhi: Vallabh Prakashan; 1995. p. 335-375.
8. Chien YW. Controlled and modulated-release drug delivery systems. In: Swarbrick J, Balyan JC, editors. Encyclopedia of Pharmaceutical Technology. New York: Marcel Dekker; 1990. p. 281-313.
9. Chien YW. Novel Drug Delivery Systems. 2nd ed. New York: Marcel Dekker, Inc.; 1992.
10. Colombo P, Bettini R, Catellani PL, Santi P, Peppas NA. Drug volume fraction profile in the gel phase and drug release kinetics in hydroxypropylmethyl cellulose matrices containing a soluble drug. Eur J Pharm Sci 1999;9:33-40.
11. Colombo P, Bettini R, Massimo G, Catellani PL, Santi P, Peppas NA, et al. Drug diffusion front movement is important in drug release
control from swellable matrix tablets. J Pharm Sci 1995;84:991-7.
Statistics
149 Views | 89 Downloads
Citatons
How to Cite
Pg*, M. “FORMULATION AND EVALUATION OF VENLAFAXINE HYDROCHLORIDE SUSTAINED RELEASE MATRIX TABLET”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 11, no. 16, Dec. 2018, pp. 170-4, doi:10.22159/ajpcr.2018.v11s4.31729.
Section
Original Article(s)